Implied Volatility Surging for Neurocrine Biosciences (NBIX) Stock Options
Oppenheimer Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Cuts Target Price to $192
BMO Capital Maintains Market Perform on Neurocrine Biosciences, Lowers Price Target to $114
Is Neurocrine Biosciences, Inc. (NBIX) the Most Promising Biotech Stock According to Hedge Funds?
Express News | Neurocrine Biosciences Inc : Leerink Partners Cuts Target Price to $160 From $170
Piper Sandler Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Maintains Target Price $159